Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Bullish On TOST & LLY
11:38am, Wednesday, 15'th May 2024
Should traders remain bullish with the current macro environment? Tom Plumb says that a good sustainable business plan, good people, disciplined allocation of capital, high return on capital, and prof
How Are Eli Lilly's Profit Margins Trending?
11:00am, Wednesday, 15'th May 2024
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (I
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
10:56am, Wednesday, 15'th May 2024
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
10:52am, Wednesday, 15'th May 2024
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
08:00am, Wednesday, 15'th May 2024
INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance
These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
05:44am, Wednesday, 15'th May 2024
Eli Lilly's top line is expanding quickly for such a large business. Two closely related drugs are to credit for much of the growth.
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
05:58pm, Tuesday, 14'th May 2024
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
02:35pm, Tuesday, 14'th May 2024
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
2 Top Pharma Stocks That Just Keep Getting Better and Better
09:53am, Tuesday, 14'th May 2024
Eli Lilly and Novo Nordisk are competing in treating diabetes and obesity. Both have launched successful products in these two markets.
Is Eli Lilly's Latest Deal a Gamechanger?
07:30am, Tuesday, 14'th May 2024
Demand for weight-loss medications such as Ozempic and Mounjaro is soaring. Eli Lilly, the developer of Mounjaro and Zepbound, is investing heavily to meet demand.
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
06:30am, Tuesday, 14'th May 2024
Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smal
3 Magnificent Stocks That Are Passive Income Machines
06:30am, Tuesday, 14'th May 2024
Eli Lilly is an ideal stock for growth and dividends. AbbVie is a Dividend King with a bright future.
Is Eli Lilly Stock A Better Pick Over Amgen?
08:30am, Monday, 13'th May 2024
Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the luc
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
07:00am, Monday, 13'th May 2024
High interest rates are here to stay. Federal Reserve Chairman Jerome Powell said the fight against inflation had stalled and the central bank was leaving interest rates unchanged.
1 No-Brainer Growth Stock to Buy and Hold
08:45am, Saturday, 11'th May 2024
Eli Lilly hit it out of the park once again with its latest financial results. The company has several regulatory catalysts on the horizon.
